VTE Risk in Patients With Cancer Receiving First-Line Immune Checkpoint Inhibitor vs Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy
Am. J. Hematol 2023 May 10;[EPub Ahead of Print], A Li, SB May, J La, KL Martens, CI Amos, CR Flowers, NV Do, MT Brophy, V Chitalia, K Ravid, JM Gaziano, NR FillmoreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.